Prime Medicine, Inc.
PRMEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePrime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. The company carries a $665.7M market cap, placing it firmly in the small-cap category. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma.
Market Cap
$665.7M
Beta
2.38
P/E (TTM)
—
P/E (Fwd)
-4.13
EPS (TTM)
$-1.07
EPS (Fwd)
$-0.89
ROE
-373.3%
ROA
-46.5%
Cash
$95.1M
Total Debt
$112.5M
Free CF
-$75.8M
52W Change
-28.7%
Annual Financials
Cash vs Debt
Where PRME stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, PRME finished 3.58% above its 150-day moving average ($3.35) and 0.29% below its 200-day moving average ($3.48). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PRME overbought or oversold?
At the October 19, 2026 close, PRME's RSI(14) was 58.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $95.1M in cash, though total debt stands at $112.5M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$75.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -373.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Prime Medicine, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Prime Medicine, Inc. and its sector.